Lawrence Otto Klein - 09 Jun 2026 Form 4 Insider Report for Jade Biosciences, Inc. (JBIO)

Reporting relationship: Director
Issuer ticker: JBIO
Reported as of: 09 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Jun 2026, 16:41:19 UTC
Prior SEC filing: 17 Mar 2026
Next SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth Balta, as attorney-in-fact for Lawrence Otto Klein

Key filing fact

Lawrence Otto Klein filed Form 4 for Jade Biosciences, Inc. (JBIO) on 11 Jun 2026.

Key facts

This page summarizes Lawrence Otto Klein's Form 4 filing for Jade Biosciences, Inc. (JBIO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Jun 2026, 16:41.

Change

Previous filing in this sequence was filed on 17 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001762583 Primary reporting owner

Klein Lawrence Otto

Relationship: Director
Address: C/O JADE BIOSCIENCES, INC., 221 CRESCENT ST., BLDG. 23, STE. 105, WALTHAM
Signature: /s/ Elizabeth Balta, as attorney-in-fact for Lawrence Otto Klein
Signature date: 11 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

JBIO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +34,843
Change %
Price: $0.000000^*
Shares after: 34,843
Date: 09 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 34,843
Exercise price: $15.22
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continued service to the Issuer.